Filing summary
Issuer and period: The supplied filing is ITUS Corporation’s unaudited Form 10-Q for the quarter ended April 30, 2016, covering the three- and six-month periods then ended. This does not match the request metadata naming Anixa Biosciences Inc.; verify the issuer before relying on this summary.
Business context and outlook
ITUS described early-detection, non-invasive blood tests for solid-tumor cancers as its expected primary focus. It was working with The Wistar Institute to validate its methods and conduct a more extensive study. The company cited favorable results from initial testing of a small group of breast-cancer patients and healthy controls, but the filing provides no results from the ongoing larger study. Legacy patent licensing continued at a limited level; a thin-film-display development project was discontinued in February 2016.
Management believed, based on information available May 20, 2016, that cash, short-term investments, and expected cash flows would fund activities for at least 12 months. It cautioned that actual cash needs could differ and said it might seek equity or debt financing; unavailable financing or inability to reduce expenses could require curtailing or ceasing operations. No financial guidance was provided.
Financial highlights
| Metric | Three months ended April 30 | Six months ended April 30 |
|---|---|---|
| Revenue | $0 in 2016; $25,000 in 2015 | $0 in 2016; $9.16 million in 2015 |
| Operating costs and expenses | $1.148 million in 2016; $2.158 million in 2015 | $2.621 million in 2016; $7.437 million in 2015 |
| Net income (loss) | $(1.272) million in 2016; $(2.237) million in 2015 | $(2.865) million in 2016; $1.516 million in 2015 |
| Basic and diluted EPS | $(0.15) in 2016; $(0.26) in 2015 | Basic $(0.33) in 2016 and $0.17 in 2015; diluted $(0.33) and $0.16 |
With no current-period revenue, a revenue margin is not meaningful. Six-month operating cash use was $1.884 million, versus $2.874 million provided in the prior-year period. Investing activities provided $109,000 and financing activities provided $18,000. Cash declined by $1.757 million during the six months.
At April 30, 2016, cash and cash equivalents were $2.612 million and short-term certificates of deposit were $2.150 million, totaling $4.762 million in cash and short-term investments. Total assets were $7.206 million; total liabilities were $4.646 million; and shareholders’ equity was $2.560 million. The $3.939 million patent-acquisition obligation is the principal disclosed long-term obligation; it is due no later than November 2017, and the November 2017 payment may be made in cash or common stock at the company’s option. The filing reports no conventional interest-bearing borrowings. No clear gross or operating margin measure is provided.
Material changes and unusual items
- Six-month revenue fell from $9.16 million to zero, primarily because the prior-year period included $9.0 million from the AU Optronics settlement and $160,000 of licensing revenue. The settlement related to thin-film-display patents and litigation.
- Six-month marketing, general and administrative expense declined by about $1.347 million to $2.383 million, principally due to lower employee and consultant stock-option expense and lower consulting, legal, and other costs. This was partly offset by higher outside research and development and investor-relations expenses.
- Six-month litigation and licensing expense declined to $75,000 from $3.440 million, with the prior-year amount primarily associated with the AUO settlement. Interest expense rose to $251,000 from $218,000, reflecting accretion on the patent-acquisition obligation rather than cash interest payments.
- Stock-based compensation was $330,000 for the six months, compared with $1.558 million in the prior-year period. The company granted options to purchase 545,000 shares during the six months and reported 8,739,659 common shares outstanding on May 16, 2016.
Risks, contingencies, and controls
The company’s ability to fund operations depends on its cash resources, expected cash flows, and potential access to financing; additional equity or convertible debt could dilute shareholders. The patent obligation’s fair-value measurement uses Level 3 inputs. The filing reports no material changes to the risk factors in the 2015 Form 10-K and no material pending legal proceedings apart from ordinary-course matters and patent-enforcement suits. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm that ITUS Corporation, rather than Anixa Biosciences Inc., is the intended issuer and that the April 30, 2016 period is the intended reporting period.
- Review the larger Wistar study’s design, sample size, results, and development timeline; the preliminary findings described here came from a small group.
- Assess cash burn against the stated 12-month runway, including the assumptions behind expected cash flows and potential financing needs.
- Verify the patent-acquisition obligation’s payment schedule, royalty offsets, and potential stock-settlement terms.
- Evaluate potential dilution from outstanding options, warrants, convertible preferred stock, and any future financing.